America’s response to the drug-abuse epidemic has been woefully inefficient and, according to most experts, counterproductive. Since 1999, nearly 841,000 people have died from a drug overdose, and the country’s choice to address drug abuse and addiction as a criminal issue rather than a health matter has only exacerbated the problem.
As it is widely acknowledged that the war on drugs was an unmitigated failure, drug-reform experts have proposed numerous public health-focused solutions that would see individuals suffering from drug addiction are given the proper medical care they deserve. One of these solutions has been quite controversial and faces an uphill battle before it is implemented on a large scale. Fortunately, a large group of law enforcement officials has offered its support for this solution and urged authorities to support its implementation as it has the potential to save plenty of lives.
The coalition of 80 former and current law enforcement officials, including President Joe Biden’s pick for the U.S. attorney of Massachusetts, has filed a brief imploring the U.S. Supreme Court to take on a case that would establish the legality of safe injection sites. These are facilities designed to provide a safe, hygienic space where people can use illicit recreational drugs intravenously in a medically supervised environment as part of a harm-reduction approach to treating drug addiction.
Safehouse, a Philadelphia-based nonprofit that provides a range of overdose prevention services, was poised to launch a safe consumption site in the state when the Trump administration blocked the move. After the nonprofit filed a petition with the Supreme Court last month to hear the case, the group of law enforcement officials is now is asking the highest court in the country to act in an amicus brief.
Overdose prevention sites are one of the harm-reduction and public-health interventions that are known to prevent deaths from drug overdoses as well as limit the number of “unnecessary and counterproductive” interactions addicts have with the justice system, they say. The group notes that adhering to prohibitionist policies that see drug abuse and addiction as a criminal issue at the expense of actual lives would only serve to further erode the public’s trust in the justice system.
As such, the group wrote in its, the Controlled Substances Act should not be used to prohibit the operation of lifesaving overdose prevention facilities. The brief states that once an individual overdoses, any delay in receiving treatment significantly increases their risk of suffering major injury and death. By ensuring that these individuals are close to qualified medical professionals and opioid reversal agents such as Naloxone, America will make great strides towards preventing fatal opioid overdoses.
The use of medical marijuana as an alternative to conventional pain medication is on the rise, and since millions of doses of opioids are prescribed annually for chronic pain, companies such as Simply Sonoma Inc., which makes medicinal products from cannabis, are making a contribution towards taming the opioid crisis.
NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.